XML 87 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Arrangements and Licensing Agreements, Novartis (Details)
$ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2019
USD ($)
shares
Jul. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
PerformanceObligation
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]            
Sublicense fee paid in stock $ 75,000          
Additional shares of Akcea stock received (in shares) | shares 2.8          
Proceeds from sale of common stock to Novartis in a private placement       $ 0 $ 0 $ 50,000
Revenue       1,122,599 599,674 514,179
R&D Revenue [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue       770,149 344,752 $ 394,165
Novartis [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Shares issued (in shares) | shares     1.6      
Proceeds from sale of common stock     $ 100,000      
Number of separate performance obligations | PerformanceObligation     4      
Transaction price     $ 108,400      
Premium received on shares issued     28,400      
Potential premium received if common stock is purchased in the future     5,000      
Deferred revenue       $ 0 $ 28,800  
Novartis [Member] | Revenue [Member] | Strategic Partner [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Concentration percentage       17.00% 8.00% 8.00%
Novartis [Member] | R&D Services for AKCEA-APO(a)-L [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     64,000      
Novartis [Member] | Delivery of AKCEA-APO(a)-L [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     1,500      
Novartis [Member] | R&D Services for AKCEA-APOCIII-L [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     40,100      
Novartis [Member] | Delivery of AKCEA-APOCIII-L [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Transaction price     2,800      
Novartis [Member] | R&D Revenue [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue       $ 187,400 $ 50,600 $ 43,400
Akcea [Member] | Novartis [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Upfront payment received     75,000      
Portion of upfront payment retained     60,000      
Portion of upfront payment paid as sublicense fee     15,000      
Percentage of license fees, milestone payments and royalties paid as sublicense fee       50.00%    
Additional amount of common stock required to be purchased     $ 50,000      
Proceeds from sale of common stock to Novartis in a private placement   $ 50,000        
Akcea [Member] | Novartis [Member] | License Fees [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Revenue $ 150,000          
Akcea [Member] | Novartis [Member] | AKCEA-APO(a)-L [Member]            
Collaborative Arrangement and Licensing Agreement [Abstract]            
Maximum amount of payments receivable for milestones       $ 675,000    
Maximum amount of payments receivable for development milestones       25,000    
Maximum amount of payments receivable for regulatory milestones       290,000    
Maximum amount of payments receivable for commercialization milestones       $ 360,000    
Royalty percentage received on sales of drug       20.00%